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Quantitation of Exposure to Benzo[aJpyrene
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by Regina M. Santella,* Ling-Ling Hsieh,* Chen-Dao Lin,*
Susan Viet,* and 1. Bernard Weinstein*
It is now possible to quantitate carcinogen adducts on DNA by highly sensitive immunoassays. These
techniques areparticularlyusefulforscreeninghumanpopulationsforexposuretopotential environmental
carcinogens. We have developed a panel of monoclonal antibodies that react with benzo(a)pyrene (BP)
modified DNA to be used in an enzyme linked immunoassay (ELISA) to quantitate adduct levels of both
human and animal samples. BALBc/Cr mice were immunized with either DNA modified by 7f,8a-dihy-
droxy-9a,10a-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BPDE-I-DNA) complexed electrostatically to
methylated bovine serum albumin or with BPDE-I-modified guanosine conjugated with bovine serum
albumin (BPDE-I-G-BSA). Four stable clones were produced from the spleen cells ofanimals immunized
with BPDE-I-DNA and one from BPDE-I-G-BSA immunized animals. All antibodies were shown to be
highly specific for BPDE-I-DNA and did not crossreact with nonmodified DNA or with N-2-acetylamino-
fluorene or 1-aminopyrene modified DNA. The antibodies differed in their sensitivity to BPDE-II-DNA,
BPDE-I-poly G, BPDE-I-tetraols and BPDE-I-dG. In general, all the antibodies showed the greatest
affinityfortheiroriginal antigen. Thosegenerated against modified DNAshowedhighestreactivity against
modified DNA while the one antibody generated against the monoadduct showed highest reactivity with
the monoadduct. These antibodies are currently being used in a highly sensitive competitive ELISA to
quantitate levels of BP-DNA adducts in various animal and human tissue samples.
Benzo(a)pyrene (BP) is a carcinogenic polycyclic ar-
omatic hydrocarbon found in heavily polluted air, cig-
arette smoke, and smoked foods. It is also a ubiquitous
contaminant in food and water. Extensive studies from
severallaboratories haveimplicated aspecificdiol epox-
ide derivative of BP, 7,,8a-dihydroxy-9a,10a-epoxy-
7,8,9,10-tetrahydrobenzo(a)pyrene (BPDE-I), as the
major electrophilic, mutagenic, and carcinogenic me-
tabolite ofBP involved in covalent binding to DNA (1).
The complete structure and conformation ofthe adduct
formed between BPDE-I and DNA in vitro is known.
It results from binding ofthe C-10 position of BPDE-I
to the 2-amino group of guanosine and is designated
BPDE-I-dG (1,2). This adduct has been detected as the
major DNA adduct found when a variety of human,
bovine, and rodent cells are exposed to BP in culture
(2-5).
Recently it has become possible to quantify carcino-
gen adducts on DNA by immunologic methods (6,7).
Since the DNA does not have to be radiolabeled, these
techniques can be used on human samples to screen for
exposure to potential environmental carcinogens. Po-
lyclonal rabbit antibodies (8-12) as well as monoclonal
antibodies(13-16) have been developed to several car-
cinogen-DNAadducts. Theuseoftheseantibodieswith
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highly sensitive immunoassays has led to the detection
of femtomole levels of carcinogens in pug quantities of
DNA (17-20). With this level ofsensitivity (betterthan
one adduct per 107 nucleotides), it is now feasible to
monitor human populations for exposure to certain car-
cinogens. Previously a rabbit antibody to BPDE-I-dG
was generated in animals immunized with BPDE-I-
modified DNA (12). This antiserum has been used in an
enzyme-linked immunosorbent assay(ELISA)toscreen
human samples for BP binding (21). Low but detectable
levels ofBPDE-I-DNA adducts were seen in lung DNA
samples from five lung cancer patients. We decided to
develop a panel of monoclonal antibodies to BPDE-I-
modified DNA because oftheir high specificity to a sin-
gle antigenic determinant and the possibility of a per-
manentsupplyofantibodies fromlong-termcellcultures
(22).
Materials and Methods
Chemicals
±BPDE-I [7p,8a-dihydroxy-9a,10a-epoxy-7,8,9,10-
tetrahydrobenzo(a)pyrene, also designated "anti"] and
±BPDE II [7,B,8a-dihydroxy-9,,10,B-epoxy, 7,8,9,10-
tetrahydrobenzo(a)pyrene, also designated "syn"] were
obtained from the Cancer Research Program ofthe Na-SANTELLA ET AL.
tional Cancer Institute (Div. of Cancer Cause and Pre-
vention, Bethesda, MD). Calfthymus DNA, goat anti-
mouse IgG and goat anti-rabbit IgG-alkaline phospha-
tase conjugates, and p-nitrophenyl phosphate (Sigma
104) were purchased from Sigma (St. Louis, MO). Rab-
bit anti-mouse IgG1, IgG2, IgM or kappa chains were
purchased from Litton Bionetics (Charleston, SC). The
media F12 (HAM's) and Iscove's modified Dulbecco's
Medium (IMDM) were purchased from Grand Island
Chem. Co. (Grand Island, NY). Fetal calfserum (FCS)
was purchased from Sterile Systems (Logan, UT).
Synthesis of Immunogens and
Immunization
Calfthymus DNA was modified in vitro with BPDE-
I to a level of 1% as described previously (23) and den-
atured before immunization. BPDE-I-G-BSA was pre-
pared by periodate treatment ofguanosine, followed by
modification with BPDE-I then coupling to BSA. De-
tails have been published (22).
BALBc/Cr mice (West Seneca Lab., W. Seneca, NY)
were treated as follows: week 1, intraperitoneal (IP)
injection of100 ,ug BPDE-DNA complexed with an equal
amount ofmethylated bovine serum albumin (mBSA) and
emulsified with an equal volume ofcomplete Freunds ad-
juvant (FA); week 3, 200 ,ug BPDE-DNA-mBSA com-
plex with incomplete FA (IP); week 5, 75 pLg BPDE-
DNA-mBSA complex with incomplete FA (IP), week 7,
50 ,ug BPDE-DNA-mBSA complex without FA, intra-
venous injection in tail vein.
A similar immunization schedule was followed for
BPDE-I-G-BSA except that the amounts used were:
week 1, 100 ,ug BPDE-I-G-BSA emulsified with com-
plete FA; week 3, 100 pug BPDE-I-G-BSA with incom-
pleteFA;week5, 75,tgBPDE-I-G-BSAwithincomplete
FA; week 7, 50 ,ug BPDE-I-G-BSA without adjuvant.
During week 6, blood samples were removed from
the tail and assayed by ELISA for antibody activity as
described below.
Cell Fusion
Spleen cells were removed 3 days after the final im-
munization and fused with the myeloma cell line
P3X63Ag8.653 using polyethylene glycol. The hybrid
cells were cultured in a HAT basal media (F12/IMDM
+ a-thioglycerol + progesterone + Pen-strep)with 10%
FCS in 10 96-well tissue culture plates. Culture super-
natants were assayed for the presence of specific anti-
bodies by ELISA. Cells from positive wells were
subcloned in argarose plates containing an underlying
monolayer of CREF cells. Details of the media prepa-
ration, fusion, and subcloningprocedure have been pub-
lished (22).
Enzyme-Linked Immunosorbent Assays
Polystyrene U bottom micro plates (Corning #25855)
were coated with 20 ng heat-denatured BPDE-I-DNA
(modified to an extent of 0.54%) in PBS, by drying at
37°C overnight. Theplateswerethenwashed withPBS-
Tween using an automatic plate washer (Flow Multi-
wash, McLean, VA.) set for five 200 ,uL washes. A
similar wash step was done after each incubation. Non-
specific binding to the plate was then minimized by in-
cubating the wells with 200 pL 1% FCS in PBS-Tween
for 1 hr. The hybridoma supernatants were then trans-
ferred to the coated plates. After a 1.5 hr incubation
37°C, the plates were washed and goat anti mouse IgG-
alkaline phosphatase (diluted 1:1000, 0.1 mL) was then
added and the plate incubated for 1.5 hr. Afterwashing
the plates with PBS-Tween, 0.1 mLp-nitrophenyl phos-
phate in 1 M diethanolamine (pH 8.6) was added to each
well. The plates were incubated for 60 min and the color
development at 405 nm was read on a Flow Multiscan
MC micro plate reader. Positive cultures were thenres-
creened by adding 50 ,uL oftheir supernatants to each
ofthree wells, one coated with BPDE-I-DNA, one coated
with unmodified DNA, and one blank, i.e., a well con-
taining no DNA. This process eliminated those clones
producing antibodies to unmodified DNA or to some
unknown antigen present in the uncoated plate.
Sera from the immunized mice were also titered by
this procedure. Various dilutions of the sera (100 ,uL)
were added to sets ofthree wells, one blank, uncoated
well, anunmodified DNA coated well, and one well coated
with BPDE-I-DNA. Those animals showingthe highest
titer against modified DNA were selected for fusion.
For the competitive assay, wells were coated with 5 ng
denatured BPDE-I-DNA (0.54% modified). The hybri-
doma supernatant was diluted and mixed with an equal
volume of the competitor before adding 0.1 mL of this
mixture to the well. Further steps were as described
above.
Isotype Determination
Hybridomasupernatant (0.1 mL of1:500dilution) was
added to wells coated with 5 ng BPDE-I-DNA. After
incubation, rabbit antisera specific for mouse IgGj, IgG2,
IgM or kappa chains (1:500 dilution) were added for 1.5
hr. This step was followed by the addition ofgoat anti
rabbit IgG-alkaline phosphatase (1:500) for 1.5 hr. The
substrate was then added and the enzyme activity de-
termined as described above.
Results
Immunization ofmicewith eitherBPDE-I-DNA com-
plexed to methylated BSA or with BPDE-I-G-BSA led
to the production of stable clones producing antibody
specific for BPDE-I-DNA. A total of five clones have
been isolated and characterized (Table 1). One clone
designated 8E11 was obtained from the spleen cells of
a BPDE-I-G-BSA immunized animal while four clones
designated 5D11, 5D2, 1D7, and 4C2 were from the
spleen cells of several BPDE-I-DNA immunized ani-
mals. Only antibody 5D11 is ofthe IgG2, kappaisotype,
all others are IgGj, kappa.
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Table 1. Immunogen and isotype analysis of antibodies.
Antibody Immunogen Isotype
8E11 BPDE-I-G-BSA IgGl, kappa
5D11 BPDE-I-DNA:MBSA IgG2, kappa
5D2 BPDE-I-DNA:MBSA IgGl, kappa
1D7 BPDE-I-DNA:MBSA IgGl, kappa
4C2 BPDE-I-DNA:MBSA IgGl, kappa
Noncompetitive ELISA was utilized to reveal the
specificity of the antibodies. Micro plates were coated
with increasing amounts of denatured modified or non-
modified DNA. For antibody 5D11, the absorbance at
405 nm, a measure of antibody binding to the plate,
increases with increasing amounts of BPDE-I-DNA
coating (Fig. 1). At higher levels a decrease in antibody
binding is seen. This is typical of the decrease in de-
tection seen at high antigen levels in solid-phase assays
(24). There is a low, but detectable level of antibody
bound to nonmodified DNA coated wells. The lowest
amount ofmodified DNAthat canbedifferentiated from
unmodified DNA (a 3-fold difference in absorbance) is
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FIGURE 1. Noncompetitive binding ofmonoclonal antibody 5D11 to
increasing amounts ofDNA. The indicated amounts ofunmodified
calfthymus DNA (m) or BPDE-I-modified DNA(0.54%) (0) were
absorbed to each well. The antibody was used at a 1:500 dilution.
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FIGURE 2. Competitive inhibition ofmonoclonal antibody 5D11
binding to BPDE-I-DNA. The competitors were(A) native BPDE-
I-DNA, (0) denatured BPDE-I-DNA, and (U) BPDE-I-RNA.
The antibody was used at a 1:10,000 dilution.
0.2 ng DNA or 3 fmole of bound BPDE-I.
CompetitiveELISAswereusedtodeterminethesen-
sitivity ofthe antibodies and to obtain additional infor-
mation about their specificity. Figure 2 shows that
antibody 5D11 differs in its reactivity with modified
native and denatured DNA. With native DNA, 50%
inhibitionis at 180fmole BPDE-I-dG adduct, while with
denatured DNA it is at 19 fmole. The antibody is even
less reactive with modified RNA (50% inhibition at 18,000
fmole). The highest sensitivity ofthe antibody is for its
original immunogen, denatured modified DNA. The
specificity of5D11 was also tested against BPDE-I-dG,
the monoadduct isolated from modified DNA, BPDE-I-
tetraols, the hydrolysis products ofBPDE-I, and BPDE-
II modified DNA. Figure 3 shows there is no cross-
reactivitywithfreetetraolswhileBPDE-I-dGhasa50%
inhibition at 21,000 fmole compared to 19 fmole for den-
atured BPDE-I-DNA. The higher reactivity with DNA
compared to monoadduct suggests that the antibody
recognizes antigenic determinants in the surrounding
DNAstructure. Whentested withBPDE-II-DNA, 50%
inhibitionwas at4400fmoleindicatingthatthe antibody
is sensitive to the stereochemistry of the BP
chromophore.
This canbe contrasted with antibody 8E11 which was
generated against the monomeric adduct coupled with
BSA. It has a lower sensitivity to BPDE-I-DNA (50%
inhibition at 350 fmole) than 5D11 (50% inhibition at 19
fmole). (Fig. 4). However, it has betterreactivity against
the monoadduct BPDE-1-dG (50% inhibition at 145fmole)
than with DNA. In addition, it shows good cross-reac-
tivity against BPDE-I tetraols (50% at 250 fmole). This
suggests that the antibody recognizes mainly determi-
nants present on the BP ring. It is specific for BPDE-
I since it does not react with BPDE-II-DNA.
The sensitivity of antibodies 5D2, 4C2, and 1D7 for
denatured BPDE-I-DNA is shown in Figure 5. Anti-
body 5D2 is the most sensitive with a 50% inhibition at
17 fmole while the values for 4C2 and 1D7 are 160 and
370 fmole, respectively.
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FIGURE 3. Competitive inhibition ofmonoclonal antibody 5D11
binding to BPDE-I-DNA. The competitors were (0) BPDE-I-
DNA, (U) BPDE-I-dG, (A) BPDE-I tetraol, and (*) BPDE-II-
DNA. The antibody was used at a 1:5000 dilution.
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FIGURE 4. Competitive inhibition of monoclonal antibody 8E11
binding to BPDE-I-DNA. The competitors were (m) BPDE-I-
DNA, (m) BPDE-I-dG, (A) BPDE-I-tetraol, and (*) BPDE-II-
DNA. The antibody was used at a dilution of 1:5,000.
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FIGURE 5. Competitive inhibition ofmonoclonal antibodybindingto
BPDE-I-DNA. (0) antibody 5D2 was used at a 1:20,000 dilution;
(A) antibody 4C2 at 1:3,000 dilution; and (U) antibody 1D7 at
1:2,000 dilution.
Table 2. Competitive inhibition of monoclonal antibody binding.
Level causing 50% inhibition, fmole
8E11 5D11 5D2 4C2 1D7
BPDE-I-DNA 350 19 17 160 370
BPDE-I-dG 145 21000 >10ka >10k 40000
BPDE-I-tetraols 250 >10," 90000 64000 1200
BPDE-I-RNA 580 18000 20000 2100 900
BPDE-II-DNA >3 x 10 4400 > 10k >lek 8800
BPDE-II-dG >le >1k >105 >105 6200
AAF-DNA >le5 >lo5a >lO5a >lo5a >lo5a
AP-DNA >1.5 x l4b >1.5 x l04b >105a >105a >l5
aNo inhibition detected with 10C fmole per assay.
bNo inhibition detected with 1.5 x 104 fmole per assay.
'No inhibition detected with 3 x 104 fmole per assay.
Table 2 summarizes all the data on the specificity and
sensitivity of the antibodies. The four antibodies gen-
erated from animals immunized with BPDE-I-DNA show
their highest reactivity to DNA with a greater than
1000-fold difference in reactivity between DNA and
monoadduct. The one antibody generated to the mon-
oadduct, however, shows a near2-fold higherreactivity
with the monoadduct than the DNA. All are fairly spe-
cific for BPDE-I adducts showing much lower cross-
reactivity with BPDE-II-dG and BPDE-II-DNA. Two
other carcinogen-modified DNAs were tested for anti-
body binding. Neither N-2-acetylaminofluorene or 1-
aminopyrenemodifiedDNAshowed anycross-reactivity
with any ofthe antibodies when tested at high concen-
trations.
The dependence of antibody reactivity on the sec-
ondary structure ofthe nucleic acids was shown by the
difference in reactivity of antibody 5D11 to native and
denatured BPDE-I-DNA. Studies with antibody 8E11
indicated that it reacts with a relatively similar sensi-
tivity with the BPDE-1 chromophore whether it was
free in solution (BPDE-I-tetraols), on dG or on DNA.
However, when tested with BPDE-I-poly G, 50% in-
hibition was at 20,000 fmole. After treatment with NaOH
to generate monoribonucleotides and neutralization the
50% inhibition dropped to 360 fmole. These studies in-
dicate that the secondary structure of the nucleic acid
can interfere with antibody binding
quantitation of modification levels.
and, therefore,
Testing of Human Samples
In a competitive ELISA it is possible to test a max-
imumof50 ,gofDNAin awell. If20% inhibition (about
5 fmole with antibody 5D11) is considered the lower
limit of sensitivity in the assay, it is possible to quan-
titate levels of adducts in the range of 1 per 107 to 10'
bases. This high level ofsensitivity is especially impor-
tant for quantitating DNA damage in human tissues,
where the expected levels ofDNA modification are likely
to be extremely low. We are currently using the mono-
clonal antibodies described in this paper to continue
studies on quantitating BP levels in human and animal
samples (17,21). The use of monoclonal antibodies and
further improvements in the sensitivity of the immu-
noassays will hopefully further facilitate human moni-
toring and provide a valuable tool in studies of human
cancer causation.
The authors express their appreciation to Dr. L. Cleveland forhelp
in fusion techniques, to Dr. B. Erlanger, and Dr. D. Grunberger for
helpful discussion and to Ms. SueAllenforsecretarial assistance. This
work was supported by The Council For Tobacco Research-U.S.A.,
Inc., No. 1483.
z
0 co I-
z
00
10
10
10
0 I
I 10 100 1000
98MONOCLONAL ANTIBODIES TO BPDE-I-DNA
REFERENCES
1. Jeffrey, A. M., Kinoshita, T., Santella, R. M., and Weinstein, I.
B. The chemistry of polycyclic aromatic hydrocarbon-DNA ad-
ducts. In: Carcinogenesis: Fundamental Mechanisms and Envi-
ronmental Effects (P. 0. P. Ts'o and H. Gelboin, Eds.), D. Reidel
Publ., Boston, 1980, p. 565.
2. Jeffrey, A. M., Weinstein, I. B., Jennette, K. W., Grzeskowiak,
K., Nakanishi, K., Harvey, R. G., Autrup, H., and Harris, C.
Structures ofbenzo[a]pyrene-nucleic acid adducts formed in hu-
man and bovine bronchial explants. Nature 269: 348-350 (1977).
3. Koreeda, M., Moore, P. D., Wislocki, P. G., Levin, W., Conney,
A. H., Yagi, H., and Jerina, D. M. Binding of benzo[a]pyrene
7,8-diol-9,10-epoxide to DNA, RNA and protein of mouse skin
occurs with high stereoselectivity. Science 199: 778-781 (1978).
4. Ivanovic, V., Geacintov, N., Yamasaki, H., and Weinstein, I. B.
DNA and RNA adducts formed in hamster embryo cell cultures
exposed to benzo[a]pyrene. Biochemistry 17: 1597-1603 (1978).
5. Shinohara, K., and Cerutti, P. A. Excision repair of BP-deoxy-
guanosine adducts in baby hamster kidney cells and in secondary
mouse embryo fiberblasts. Proc. Natl. Acad. Sci. (U.S.) 74: 979-
983 (1977).
6. Rajewsky, M. F., Muller, R., Adamkiewicz, J., and Drosdziok,
W. Immunological detection and quantification of DNA com-
pounds structurally modified by alkylating carcinogens ethylni-
trosourea. In: Carcinogenesis: Fundamental Mechanisms and
Environmental Effects (B. Pullman, P. 0. P. Ts'o and H. V.
Gelboin, Eds.), Reidel Press, Dorbrecht, Holland, 1980, pp. 207-
218.
7. Poirier, M. C. Antibodies to carcinogen-DNA adducts. J. Natl.
Cancer Inst. 67: 515-519 (1981).
8. Poirier, M. C., Lippard, S., Zwelling, L. A., Ushay, M., Kern-
gan, D., Thill, C. C., Santella, R. M., and Grunberger, D. An-
tibodies elicited against cis-diarninedichloroplatinum(II)-modified
DNA are specific for cis-diammineplatinum(II)-DNA adducts
formed in vivo and in vitro. Proc. Natl. Acad. Sci. (U.S.) 79:
6443-6447 (1982).
9. Poirier, M. C., Yuspa, S. H., Weinstein, I. B., and Blobstein, S.
Detectionofcarcinogen-DNAadductsbyradioimmunoassay. Na-
ture 270: 186-188 (1977)
10. Leng, M., Sage, E., Fuchs, R. P., and Daune, M. P. Antibodies
to DNA modified by the carcinogen N-acetoxy-N-2-acetylami-
nofluorene. FEBS Letters 92: 207-210 (1978).
11. Muller, R., and Rajewsky, M. F. Immunological quantification
by high-affinity antibodies of 06-ethyldeoxyguanosine in DNA
exposed toN-ethyl-N-nitrosourea. Cancer Res. 40: 887-896 (1980).
12. Poirier, M. C., Santella, R., Grunberger, D., and Weinstein, I.
B. Quantitation ofbenzo[alpyrene-deoxyguanosine adductsbyra-
dioimmunoassay. Cancer Res. 40: 412-416 (1980).
13. Strickland, P. T., and Boyle, J. M. Characterisation oftwo mon-
oclonal antibodies specific for dimerised and non-dimerised ad-
jacentthymidinesinsinglestranded DNA. Photochem. Photobiol.
34: 595-601 (1981).
14. Wied, C. P., Smart, G., Saffhill, R., and Boyle, J. M. Radioim-
munoassayof06-methyldeoxyguanosine in DNAofcells alkylated
in vitro and in vivo. Carcinogenesis 4: 1605-1609 (1983).
15. Haugen, A., Groopman, J. D., Hau, I. C., Goodrich, G. R., Wo-
gan, G. W., and Harris, C. C. Monoclonal antibody to aflatoxin
Bl-modified DNA detected by enzyme immunoassay. Proc. Natl.
Acad. Sci. (U.S.) 78: 4124-4127 (1981).
16. Hertzog, P. J., Smith, J. R. L., and Garner, R. C. Production of
monoclonal antibodies to guanine imidazole ring opened aflatoxin
Bi DNA, the persistent DNA adduct in vivo. Carcinogenesis 3:
825-828 (1982).
17. Hsu, I. C., Poirier, M. C., Yuspa, S. H., Grunberger, D., Wein-
stein, I. B., Yolken, R. H., and Harris, C. C. Measurement of
benzo[a]pyrene-DNA adducts by enzyme immunoassays and ra-
dioimmunoassay. Cancer Res. 41: 1090-1095 (1981).
18. Groopman, J. D., Hauger, A., Goodrich, G. R., Wogan, G. N.,
and Harris, C. C. Quantitation of aflatoxin Bl-modified DNA
using monoclonal antibodies. Cancer Res. 42: 3120-3124 (1982).
19. Muller, R., andRajewsky, M. F. Sensitive radioimmunoassay for
detection ofO6-ethydeoxyguanosine in DNA exposed to the car-
cinogen ethylnitrosourea in vivo and in vitro. Z. Naturforsch.
C33: 897-901 (1978).
20. Van der Laken, C. J., Hagenaars, A. M., Hermsen, G., Kriek,
E., Kuipers, A. J., Nagel, J., Scherer, E., and Weling, M. Mea-
surement of 06-ethyldeoxyguanosine and N-(deoxyguanosine-8-
yl)-N-acetyl-2-aminofluorene in DNA by high-sensitive enzyme
immunoassays. Carcinogenesis 5: 569-572 (1982).
21. Perera, F. P., Poirier, M. C., Yuspa, S. H., Nakayama, J., Jar-
etzki, A., Curmen, M. M., Knowles, D. M., and Weinstein, I. B.
A pilot project in molecularcancer epidemiology: determination
ofbenzo[a]pyrene-DNA adducts in animal and human tissues by
immunoassays. Carcinogenesis 3: 1405-1410 (1982).
22. Santella, R. M., Lin, C. D., Cleveland, W. L., and Weinstein, I.
B. Monoclonal antibodies to DNA modified by a benzo[a]pyrene
diol epoxide. Carcinogenesis 5: 373-377 (1984).
23. Jennette, K. W., Jeffrey, A. M., Blobstein, S. H., Beland, F. A.,
Harvey, R. G., and Weinstein, I. B. Nucleoside adducts from the
in vitro reaction ofbenzb[a]pyrene-7,8-dihydrodiol-9, 10-oxide or
benzo[alpyrene-4,5-oxide with nucleic acids. Biochemistry 16: 932-
938 (1977).
24. Engrall, E., and Perlmann, P. Enzyme-linked immunosorbent
assay, ELISA. J. Immunol. 109: 129-135 (1972).